| Característica |
Objectiu de la convocatòria
The INTER-LOCAL call supports late-phase (Phase II/III), international clinical trials focused on local treatment interventions for rare and/or hard-to-treat cancers.
|
Característiques principals
Multinational, multicentre clinical trials in Phase II and/or Phase III, including comparable designs such as single-arm phase II trials.
Focus on rare cancers (incidence <6/100,000 per year) and/or hard-to-treat cancers with low survival rates (5-year survival <25%), addressing any stage of the disease as long as the cancer type at initial diagnosis meets the criteria.
Core experimental interventions based on local treatments, such as radiotherapy or surgery.
Strong rationale for international collaboration, including patient recruitment, harmonization of protocols, and implementation of results.
Robust plans for patient involvement, quality-of-life assessment, and long-term impact.
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact:
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: [email protected] Ext.: 1670
Marta López: [email protected] Ext.: 1576
|
Convocatòria (URL)
https://www.kwf.nl/en/forresearchers/funding/inter-local
|
Informació addicional
This call follows a two-stage submission procedure. Both pre- and full proposal must be submitted by the Project Leader through the electronic submission system no later than 12:00 PM CET on the deadline date. A webinar for applicants would be held on 9 December 2025, from 16:00 to 17:00 CET, providing practical guidance on the call and application process.
|
Requisits
Applicants must comply with individual national rules and funding conditions (see Guidelines for Budget Request).
Spanish applicants should apply through the Scientific Foundation of the Spanish Association against Cancer (FC AECC).
Each transnational consortium must include at least three National Coordinators from the five funding countries (Belgium, Netherlands, Spain, Norway and Sweden), and a Project Leader must be nominated among them. Participation of all five countries is highly encouraged.
Inclusion of centres and participating parties from other European countries is allowed.
Eligible centres include academic research groups as well as clinical or public health sector research groups.
Young researchers are welcome to participate.
Projects must actively involve patients throughout the entire project lifecycle.
|
Dotació
The Spanish contribution to the project amounts to €1 million. There is no maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget. However, it is highly recommended to respect the available budget of each funding organization.
|
Durada
Up to 6 years
|